bioMerieux (OTCMKTS:BMXMF) Shares Gap Down – Here’s Why

bioMerieux (OTCMKTS:BMXMF)’s stock price gapped down before the market opened on Monday . The stock had previously closed at $82.78, but opened at $78.31. bioMerieux shares last traded at $78.31, with a volume of 58 shares trading hands.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. UBS Group lowered shares of bioMerieux from a “buy” rating to a “neutral” rating in a report on Monday, June 1st. Piper Sandler began coverage on bioMerieux in a research note on Thursday, June 11th. They set a “neutral” rating for the company. Zacks Research raised shares of bioMerieux to a “hold” rating in a research note on Tuesday, April 28th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of bioMerieux in a report on Wednesday, June 17th. Finally, Morgan Stanley downgraded bioMerieux from an “overweight” rating to an “underweight” rating in a research note on Tuesday, June 23rd. Five analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Reduce”.

bioMerieux Price Performance

The company has a quick ratio of 1.48, a current ratio of 2.39 and a debt-to-equity ratio of 0.08. The business’s 50 day moving average price is $82.05 and its two-hundred day moving average price is $102.29.

About bioMerieux

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.